Liang Xiu

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld et al. · Journal of Clinical Oncology · 2007 · 644 citations · Full text

Slowing of age-specific mortality rates in Drosophila melanogaster

H. Henry Fukui, Liang Xiu, James W. Curtsinger · Experimental Gerontology · 1993 · 135 citations

Biology, Drosophila Melanogaster, Aging +3

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

Joseph A. Sparano, Semiglazov Vf, Sergei Tjulandin et al. · Journal of Clinical Oncology · 2009 · 116 citations · Full text

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois et al. · Leukemia · 2020 · 96 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +5

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Brian Leyland‐Jones, Igor Bondarenko, Gia Nemsadze et al. · Journal of Clinical Oncology · 2016 · 66 citations